Rossari Biotech growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+15.2%+13.6%+10.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.9%+6.1%+12.0%
+4.4%+4.6%+18.3%
+9.4%+4.4%+21.8%
+9.3%+4.2%+21.6%
+20.7%+20.6%+15.0%
+12.5%+13.1%+14.5%
−52.7%+217.8%−71.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ROSSARI₹407.60

Rossari Biotech Limited

· Chemicals
₹ CrorePeersNOCILHSCLNAVINFLUORDDEVPLSTIKCHEMPLASTSTATACHEMAARTIINDJGCHEMMcap ₹2,257 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+10.5+13.6+15.2—
EBITDA Growth—+12.0+6.1+7.9—
EBIT Growth—+18.3+4.6+4.4—
Net Income Growth—+21.8+4.4+9.4—
EPS Growth—+21.6+4.2+9.3—
Total Assets Growth—+15.0+20.6+20.7—
Total Equity Growth—+14.5+13.1+12.5—
Cash from Operations Growth—-71.6+217.8-52.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.